PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1808
https://www.valueinhealthjournal.com/article/S1098-3015(19)34186-5/fulltext
Title :
PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34186-5&doi=10.1016/j.jval.2019.09.1808
First page :
Section Title :
Open access? :
No
Section Order :
11572